<DOC>
	<DOCNO>NCT00723502</DOCNO>
	<brief_summary>The primary objective study compare H. pylori eradication rate Finafloxacin combination Amoxicillin Esomeprazole . The secondary objective evaluate compare safety tolerability multiple oral dos Finafloxacin plus Amoxicillin versus Finafloxacin plus Esomeprazole .</brief_summary>
	<brief_title>Efficacy Safety Study Finafloxacin Used Helicobacter Pylori Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Gram-Negative Bacterial Infections</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>1 . Male female patient 18 70 year old , dyspepsia dyspeptic symptom . 2 . The patient must understand nature study must provide write informed consent . 3 . Each patient must able communicate study personnel . 4 . Gastroscopic confirmation H. pylori infection Rapid Urease Test . 5 . Positive Urea Breath Test . 6 . Absence blood stool . 1 . Gastroscopic confirmation gastric ulcer . 2 . History ZollingerEllison syndrome . 3 . Gastroesophageal Reflux Disease ( GERD ) . 4 . Subtotal gastrectomy vagotomy medical history . 5 . Pyloric stenosis . 6 . Previous H. pylorus eradication therapy . 7 . Patients likely need take one follow medication within two week prior study period : antibiotic study medication ; protonpump inhibitor study medication ; NSAIDs include aspirin glucocorticoid ; 8 . Patients take antacid and/or H2blockers study period . 9 . Patients take bismuth compound within four week prior study period . 10 . Patients psychiatric , neurological , behavioral disorder may interfere conduct interpretation study . 11 . Patients severe concomitant disease cardiovascular , pulmonic , hepatic , renal , hematological , lymphatic , metabolic , endocrine system . 12 . Clinically significant serious unstable physical illness : treat , control thus stable hypertension consider exclusion criterion . 13 . Patients know uncontrolled hypertension symptomatic hypotension . 14 . Patients immunocompromised . 15 . Patients malignant disease kind except Basalioma . 16 . Patients show clinically significant abnormal vital sign . 17 . Patients clinically significant abnormal ECG finding . 18 . Clinically significant abnormal laboratory data Screening , abnormal laboratory value could interfere assessment safety . 19 . Exposure investigational drug within 30 day prior Screening . 20 . Known hypersensitivity contraindication use fluoroquinolones . 21 . Prior participation Finafloxacin study . 22 . Pregnant nursing woman , woman childbearing potential use effective contraceptive method study , e.g . oral ( stable dos least three month prior Screening ) injectable ( stable dos least two month prior Screening ) contraceptive , implantation levonorgestrel system intrauterine device ( least two month prior Screening ) , barrier method ( combination diaphragm spermicide condom spermicide ) . 23 . Current diagnosis know history substance abuse . 24 . Site personnel immediate family , define spouse , parent , child , grandparent , grandchild . 25 . Reasonable likelihood noncompliance protocol reason , investigator 's opinion , prohibit inclusion patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>Eradication</keyword>
	<keyword>Dyspepsia</keyword>
</DOC>